Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bumrungrad Hospital PCLBUGDF 100 3-Year EBITDA Growth Rate is 13.10% as of Mar. 2026, which is 33% above its 10-year median of 9.85. GuruFocus rates BUGDF with a GF Scoreâ„¢ of 100/100 and a GF Valueâ„¢ of $5.53. The stock has 1 warning sign investors should review. Among 528 Healthcare Providers & Services companies, Bumrungrad Hospital PCL ranks better than 56.25% on this metric.
During the past 12 months, Bumrungrad Hospital PCL's average EBITDA Per Share Growth Rate was 3.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 13.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 37.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 6.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Bumrungrad Hospital PCL was 56.30% per year. The lowest was -24.40% per year. And the median was 9.85% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Bumrungrad Hospital PCL 3-Year EBITDA Growth Rate Related Terms
BUGDF vs HCA, THC, DVA: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Bumrungrad Hospital PCL's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bumrungrad Hospital PCL 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Bumrungrad Hospital PCL's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Bumrungrad Hospital PCL's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 13.10% mean?
Bumrungrad Hospital PCL (BUGDF) has a 3-Year EBITDA Growth Rate of 13.10% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Bumrungrad Hospital PCL and its competitors. This is 33% above median its historical median of 9.85. According to the industry distribution chart, Bumrungrad Hospital PCL ranks #231 out of 528 companies in the Healthcare Providers & Services industry, placing it in the top 43.7%.
Is Bumrungrad Hospital PCL's 3-Year EBITDA Growth Rate too high?
Bumrungrad Hospital PCL's current 3-Year EBITDA Growth Rate of 13.10% is 33% above median its 10-year median of 9.85. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. Bumrungrad Hospital PCL's value of 13.10% is 28.4% above this industry median. Based on the distribution chart, Bumrungrad Hospital PCL ranks #231 out of 528 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Bumrungrad Hospital PCL has a GF Scoreâ„¢ of 100/100, reflecting its overall financial health beyond just this single metric.
How does Bumrungrad Hospital PCL's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Bumrungrad Hospital PCL ranks #231 out of 528 companies for 3-Year EBITDA Growth Rate. This puts Bumrungrad Hospital PCL in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.20. Bumrungrad Hospital PCL's value of 13.10% is 28.4% above this benchmark. While the company's 10-year median is 9.85 vs. the industry median of 10.20, Bumrungrad Hospital PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 528 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bumrungrad Hospital PCL's current 3-Year EBITDA Growth Rate of 13.10% is 28.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Bumrungrad Hospital PCL and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bumrungrad Hospital PCL's current 3-Year EBITDA Growth Rate is 13.10%, which is 33% above median its own 10-year median of 9.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bumrungrad Hospital PCL stock overvalued right now?
Bumrungrad Hospital PCL (BUGDF) has a current 3-Year EBITDA Growth Rate of 13.10%. The stock's GF Value™ is $5.53, compared to a current price of $4.75 — trading 14.1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 13.10%, which is 33% above median its 10-year median of 9.85 and 28.4% above the Healthcare Providers & Services industry median of 10.20. Bumrungrad Hospital PCL's overall GF Score™ is 100/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Bumrungrad Hospital PCL (BUGDF), the current 3-Year EBITDA Growth Rate is 13.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bumrungrad Hospital PCL (BUGDF) Overvalued in 2026?
Based on GuruFocus' analysis, Bumrungrad Hospital PCL stock appears to be undervalued.
The current stock price of $4.75 is trading 14.1% below its estimated GF Value™ of $5.53.
Key valuation signals for BUGDF:
3-Year EBITDA Growth Rate: 13.10% (33% above median its 10-year median of 9.85)
GF Value™: $5.53 vs. price of $4.75 (14.1% below fair value)
Industry Position: 28.4% above the Healthcare Providers & Services median (#231 of 528)
No single metric tells the full story. See the BUGDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bumrungrad Hospital PCL operates a private hospital business in Bangkok. The company operates several healthcare-related entities, within and outside of Thailand which include Bumrungrad International Hospital, Bumrungrad International Clinic, Vitallife Scientific Wellness Center, VitalLife Skin Clinic, Bumrungrad International Dialysis Clinic, and others. It is a healthcare provider in Thailand providing complete healthcare services for both outpatients and inpatients. The company is the owner and operator of multiple healthcare-related entities. The company has only one main reportable operating segment, which is the hospital and health care center business, and the geographical area of its operations is Thailand.
100GF Score
Get the complete analysis for BUGDF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUGDF has been successfully added to your 
